Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs

Journal of Controlled Release

Volumn 169, Issue 1-2, 2013, Pages 150-161

  Nkansah, Paul ^a   Antipas, Amy ^a   Lu, Ying ^b   Varma, Manthena ^a   Rotter, Charles ^a   Rago, Brian ^a   El Kattan, Ayman ^a   Taylor, Graeme ^a   Rubio, Mario ^a   Litchfield, John ^a  

^a PFIZER INC   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Furosemide; Nanodispersion; Nanoparticle; Permeability; Solid dispersion; Solubility

Indexed keywords

DISPERSION TECHNOLOGIES; FUROSEMIDES; MADIN-DARBY CANINE KIDNEY CELLS; NANO-DISPERSIONS; PHARMACEUTICAL COMPOUNDS; POLYVINYL PYRROLIDONE; POORLY WATER-SOLUBLE DRUGS; SOLID DISPERSION;

DISPERSIONS; GRINDING (MACHINING); MECHANICAL PERMEABILITY; MILLING (MACHINING); MIXTURES; NANOPARTICLES; PARTICLE SIZE; PHARMACOKINETICS; SODIUM DODECYL SULFATE; SOLUBILITY; SOLVENTS;

CHEMICAL COMPOUNDS;

CELECOXIB; DODECYL SULFATE SODIUM; FUROSEMIDE; INGLIFORIB; METHYLCELLULOSE; MULTIDRUG RESISTANCE PROTEIN 1; NANOPARTICLE; POVIDONE; SURFACTANT;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; COLLOID; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MIXTURE; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FIRST PASS EFFECT; HUMAN; HYDROPHILICITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ROOM TEMPERATURE; SOLID NANODISPERSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE; DOGS; DRUG COMPOUNDING; EQUIPMENT DESIGN; FUROSEMIDE; HUMANS; MALE; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SOLUBILITY;

EID: 84877858977     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.03.032     Document Type: Article

References (54)

1. E.M. Merisko-Liversidge, and G.G. Liversidge Drug nanoparticles: formulating poorly water-soluble compounds Toxicol. Pathol. 36 1 2008 43 48
2. A.L. Christopher Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 1 2000 235 249
3. K. Kawakami, T. Yoshikawa, Y. Moroto, E. Kanaoka, K. Takahashi, Y. Nishihara, and K. Masuda Microemulsion formulation for enhanced absorption of poorly soluble drugs: I. Prescription design J. Control. Release 81 1-2 2002 65 74 (Pubitemid 34454850)
4. G.G. Liversidge, and K.C. Cundy Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs Int. J. Pharm. 125 1 1995 91 97
5. W.P. Colin Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and self-microemulsifying drug delivery systems Eur. J. Pharm. Sci. 11 Supplement 2(0) 2000 S93 S98
6. C.M. Keck, and R.H. Muller Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation Eur. J. Pharm. Biopharm. 62 1 2006 3 16 (Pubitemid 41736019)
7. D. Horn, and J. Rieger Organic nanoparticles in the aqueous phase - theory, experiment, and use Angew. Chem. Int. Ed. 40 23 2001 4330 4361 (Pubitemid 33150759)
8. R.H. Muller, and K. Peters Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique Int. J. Pharm. 160 2 1998 229 237 (Pubitemid 28083096)
9. D. Xia, F. Cui, H. Piao, D. Cun, H. Piao, Y. Jiang, M. Ouyang, and P. Quan Effect of crystal size on the dissolution and oral absorption of nitrendipine in rats Pharm. Res. 27 9 2010 1965 1976
10. J.P. Sylvestre, M.C. Tang, A. Furtos, G. Leclair, M. Meunier, and J.C. Leroux Nanonization of megestrol acetate by laser fragmentation in aqueous milieu J. Control. Release 149 3 2011 273 280
11. J. Jinno, N. Kamada, M. Miyake, K. Yamada, T. Mukai, M. Odomi, H. Toguchi, G.G. Liversidge, K. Higaki, and T. Kimura Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs J. Control. Release 111 1-2 2006 56 64 (Pubitemid 43289995)
12. R. Lobenberg, and G.L. Amidon Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards Eur. J. Pharm. Biopharm. 50 1 2000 3 12 (Pubitemid 30326685)
13. I. Ghosh, J. Snyder, R. Vippagunta, M. Alvine, R. Vakil, W.Q. Tong, and S. Vippagunta Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder Int. J. Pharm. 419 1-2 2011 12 19
14. L. Peltonen, and J. Hirvonen Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods J. Pharm. Pharmacol. 62 11 2010 569 1579
15. S. Janssens, and G. Van den Mooter Review: physical chemistry of solid dispersions J. Pharm. Pharmacol. 61 12 2009 1571 1586
16. J. Junghanns, and R.H. Muller Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomedicine 3 3 2008 295 309
17. A.H. Goldberg, M. Gibaldi, and J.L. Kanig Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures I - theoretical considerations and discussion of literature J. Pharm. Sci. 54 8 1965 1145
18. H.M. El-Banna, N.A. Daabis, L.M. Mortada, and S. Abd-Elfattah Physicochemical study of drug binary-systems.3. tolbutamide-urea and tolbutamide-mannitol systems Pharmazie 30 12 1975 788 792
19. E.A. Fouad, M. El-Badry, G.M. Mahrous, F.K. Alanazi, S.H. Neau, and I.A. Alsarra The use of spray-drying to enhance celecoxib solubility Drug Dev. Ind. Pharm. 37 12 2011 1463 1472
20. G.W. Lu, M. Hawley, M. Smith, B.M. Geiger, and W. Pfund Characterization of a novel polymorphic form of celecoxib J. Pharm. Sci. 95 2 2006 305 317 (Pubitemid 43241973)
21. A.M. Kaushal, and A.K. Bansal Thermodynamic behavior of glassy state of structurally related compounds Eur. J. Pharm. Biopharm. 69 3 2008 1067 1076
22. V. Ambrogi, L. Perioli, C. Pagano, L. Latterini, F. Marmottini, M. Ricci, and C. Rossi MCM-41 for furosemide dissolution improvement Microporous Mesoporous Mater. 147 1 2012 343 349
23. J. Kotecha, S. Shah, I. Rathod, and G. Subbaiah Prediction of oral absorption in humans by experimental immobilized artificial membrane chromatography indices and physicochemical descriptors Int. J. Pharm. 360 1-2 2008 96 106
24. F.L. Mota, A.P. Carneiro, A.J. Queimada, S.P. Pinho, and E.A. Macedo Temperature and solvent effects in the solubility of some pharmaceutical compounds: measurements and modeling Eur. J. Pharm. Sci. 37 3-4 2009 499 507
25. M.V. Varma, C.J. Rotter, J. Chupka, K.M. Whalen, D.B. Duignan, B. Feng, J. Litchfield, T.C. Goosen, and A.F. El-Kattan pH-Sensitive Interaction of HMG-CoA Reductase Inhibitors (Statins) with Organic Anion Transporting Polypeptide 2B1 Mol. Pharm. 8 4 2011 1303 1313
26. M.P. Gibaldi, and D. Perrier Pharmacokinetics 1982 Marcel Dekker, Inc. New York
27. E.J. Kim, K.S. Han, and M.G. Lee Gastrointestinal first-pass effect of furosemide in rats J. Pharm. Pharmacol. 52 11 2000 1337 1343
28. A. Sakurai, T. Sakai, K. Sako, and Y. Maitani Polymer combination increased both physical stability and oral absorption of solid dispersions containing a low glass transition temperature drug: physicochemical characterization and in vivo study Chem. Pharm. Bull. 60 4 2012 459 464
29. Y-D. Yan, J.H. Sunga, K.K. Kima, D.W. Kimb, J.O. Kima, B-J. Leec, C.S. Yonga, and H-G. Choi Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes Int. J. Pharm. 422 1-2 2012 202 210
30. C.Q. Yang, X. Xu, J. Wang, and Z. An Use of the co-grinding method to enhance the dissolution behavior of a poorly water-soluble drug: generation of solvent-free drug-polymer solid dispersions Chem. Pharm. Bull. 60 7 2012 837 845
31. R.H. Dave, A.D. Patel, E. Donahue, and H.H. Patel To evaluate the effect of addition of an anionic surfactant on solid dispersion using model drug indomethacin Drug Dev. Ind. Pharm. 38 8 2012 930 939
32. E. Gundogdu, V. Mangas-Sanjuan, I. Gonzalez-Alvarez, M. Bermejo, and E. Karasulu In vitro-in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate Eur. J. Drug Metab. Pharmacokinet. 37 1 2012 65 75
33. S.R. Vippagunta, H.G. Brittain, and D.J.W. Grant Crystalline solids Adv. Drug Deliv. Rev. 48 1 2001 3 26 (Pubitemid 32452290)
34. E. Jantratid, N. Janssen, C. Reppas, and J.B. Dressman Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 25 7 2008 1663 1676
35. J.C. Butcher, S. Garg, D. Kim, and P. Sharma A modified approach to predict dissolution and absorption of polydisperse powders Pharm. Res. 25 10 2008 2309 2311
36. W. Wu, and G.H. Nancollas A new understanding of the relationship between solubility and particle size J. Solution Chem. 27 6 1998 521 531 (Pubitemid 128362084)
37. T. Tachibana, M. Kato, and Y. Sugiyama Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values Pharm. Res. 29 3 2012 651 668
38. W.L. Chiou, C. Ma, S.M. Chung, T.C. Wu, and H.Y. Jeong Similarity in the linear and non-linear oral absorption of drugs between human and rat Int. J. Clin. Pharmacol. Ther. 38 11 2000 532 539
39. W.L. Chiou, S.M. Chung, T.C. Wu, and C. Ma A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans Int. J. Clin. Pharmacol. Ther. 39 3 2001 93 101 (Pubitemid 32208536)
40. M.G. Lee, and W.L. Chiou Evaluation of potential causes for the incomplete bioavailability of furosemide - gastric 1st-pass metabolism J. Pharmacokinet. Biopharm. 11 6 1983 623 640 (Pubitemid 14070321)
41. W.L. Chiou, and A. Barve Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats Pharm. Res. 15 11 1998 1792 1795 (Pubitemid 28524594)
42. Y. Adachi, H. Suzuki, and Y. Sugiyama Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein Pharm. Res. 18 12 2001 1660 1668 (Pubitemid 34020420)
43. B. Feng, J.B. Mills, R.E. Davidson, R.J. Mireles, J.S. Janiszewski, M.D. Troutman, and S.M. de Morais In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system Drug Metab. Dispos. 36 2 2008 268 275 (Pubitemid 351185738)
44. S.H. Kim, Y.M. Choi, and M.G. Lee Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition J. Pharmacokinet. Biopharm. 21 1 1993 1 17 (Pubitemid 23261727)
45. S. Gosangari, and T. Dyakonov Enhanced dissolution performance of curcumin with the use of supersaturatable formulations Pharm. Dev. Technol. 18 2 2013 475 480
46. N. Marasini, T.H. Tran, B.K. Poudel, H.J. Cho, Y.K. Choi, S.C. Chi, H.G. Choi, C.S. Yong, and J.O. Kim Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique Int. J. Pharm. 441 1-2 2013 424 432
47. Y. Hida, T. Fukami, N. Suzuki, and K. Tomono Processing and formulation of drug nanoparticles by ternary cogrinding with methacrylic copolymer and sucrose fatty acid esters Adv. Powder Technol. 24 1 2013 246 251
48. T. Nassar, S. Attili-Qadri, O. Harush-Frenkel, S. Farber, S. Lecht, P. Lazarovici, and S. Benita High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation Cancer Res. 71 8 2011 3018 3028
49. W. Faisal, C.M. O'Driscoll, and B.T. Griffin Bioavailability of lycopene in the rat: the role of intestinal lymphatic transport J. Pharm. Pharmacol. 62 3 2010 323 331
50. P. Artursson, and R.T. Borchardt Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond Pharm. Res. 14 12 1997 1655 1658 (Pubitemid 28062907)
51. G.E. Granero, M.R. Longhi, M.J. Mora, H.E. Junginger, K.K. Midha, V.P. Shah, S. Stavchansky, J.B. Dressman, and D.M. Barends Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Furosemide J. Pharm. Sci. 99 6 2010 2544 2556
52. B.D. Rege, L.X. Yu, A.S. Hussain, and J.E. Polli Effect of common excipients on Caco-2 transport of low-permeability drugs J. Pharm. Sci. 90 11 2001 1776 1786 (Pubitemid 33062598)
53. Martindale: The Complete Drug Reference S. Sweetman 2009 Pharmaceutical Press, Thomson/MICROMEDEX London, UK
54. A. Grahnen, M. Hammarlund, and T. Lundqvist Implications of intraindividual variability in bioavailability studies of furosemide Eur. J. Clin. Pharmacol. 27 5 1984 595 602 (Pubitemid 15176768)